Kuhle et al. (2016) showed that NfL levels measured in blood and CSF are significantly higher in patients with relapsing forms of MS compared to healthy controls and patients with primary progressive MS (PPMS), and these levels tend to decrease with effective disease-modifying therapy (DMT) [43]. Here, NEFL is linked to myeloid sarcoma.